GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

China’s mRNA Vaccine Developer Stemirna Secures $200 Million in New Funding

by Tyler Chen
Share To

Founded by a group of Chinese scholars in Shanghai’s Zhangjiang Drug Valley, China-based Stemirna Therapeutics (Stemirna) announced the completion of a new funding round, getting $200 million richer. Hangwen Li, President, and CEO of Stemirna, said that the proceeds would be used to facilitate the clinical development and production of its mRNA COVID-19 vaccine.

The funding was led by some of the big investors in China, including China Merchants Group, Sequoia Capital China, Greenwoods Investment, and Wuxi Apptec, to name a few.

 

Vaccines for Immuno-oncology and Infectious Diseases

Stemirna’s pipeline focuses on the development of immuno-oncology and infectious disease vaccines. By utilizing its mRNA synthesis platform and LPP (lipopolyplex) nano-delivery platform, the firm has co-developed a COVID-19 mRNA vaccine candidate with China’s Tongji University, and a personalized cancer vaccine candidate.

Other than that, Stemirna plans to develop vaccines that target influenza, acute myeloid leukemia (AML), KRAS cancer, HPV, EBV by 2023.

 

mRNA COVID-19 Vaccines to Enter Phase 2 Trial

Hangwen Li said that the COVID-19 vaccine is designed to prevent the Beta (B.1.351, found in South Africa), Gamma (P.1, found in Brazil), and Delta (B.1.617.2, found in India) COVID-19 variants. It has already initiated Phase 1 clinical trials on March 25th and could soon move to Phase 2 in China. At the same time, an overseas Phase 3 trial is on the way.

Stemirna was founded in 2016, receiving around $3 million in total in the Angel round and Series A round. The firm is currently located in the Jinqiao Pilot Free Trade Zone.

Related Article: COVID-19: WHO Grants Worldwide Emergency Use Approval for First Chinese Vaccine

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
2025-01-22
Rising Bird Flu Cases in Cattle and Humans Drive Global Efforts in Vaccination, Genetic Monitoring, and Surveillance
2024-07-17
Moderna and Mitsubishi Tanabe Pharma Partner on mRNA Respiratory Vaccines in Japan
2024-07-11
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top